RSS-Feed abonnieren
DOI: 10.1055/s-0031-1286333
FINDRISK Questionnaire Combined with HbA1c Testing as a Potential Screening Strategy for Undiagnosed Diabetes in a Healthy Population
Publikationsverlauf
received13. April 2011
18. August 2011
Publikationsdatum:
18. Oktober 2011 (online)
![](https://www.thieme-connect.de/media/hmr/201111/lookinside/thumbnails/10.1055-s-0031-1286333-1.jpg)
Abstract
Despite the efforts to control the epidemic of diabetes the total number of people living with diabetes is still steadily rising. In order to detect people at risk, cost-effective, convenient, and sensitive screening tools to assess the diabetes risk and to detect undiagnosed type 2 diabetes need to be developed and implemented in the primary care setting. To evaluate the combination of the well established FINDRISK questionnaire and HbA1c testing as a potential screening strategy the data obtained from 671 blood donors were analyzed for a potential correlation with the results of an oral glucose tolerance test. Based on the oral glucose tolerance test, 65 blood donors (9.7%) were newly diagnosed with diabetes, 336 (50.1%) with prediabetes, and 270 (40.2%) had a normal test result. Of the 401 blood donors diagnosed with prediabetes or diabetes 322 (80.3%) had a HbA1c between 5.7% and 6.4% and 27 (6.7%) with a HbA1c of 6.5% or greater. The majority of the blood donors newly diagnosed with diabetes or prediabetes (n=327) had a FINDRISK result of 12 points or higher. ROC analyses confirmed that the optimal cut off levels were for FINDRISK ≥ 12 points and for HbA1c ≥ 5.9%. Thus, a 3-step screening strategy applying the FINDRISK questionnaire followed by HbA1c testing and performing an oral glucose tolerance test on selected individuals could be a cost-saving approach for screening large populations and identifying people at risk for diabetes or undiagnosed diabetes.
-
References
- 1 Ahmad LA, Crandall JP. Type 2 diabetes prevention: a review. Clinical Diabetes 2010; 28: 53-59
- 2 Hauner H, Hanisch J, Bramlage P, Steinhagen-Thiessen E, Schunkert H, Jöckel KH, Wasem J, Moebus S. Prevalence of undiagnosed Type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Exp Clin Endocrinol Diabetes 2008; 116: 18-25
- 3 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
- 4 Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
- 5 Paulweber B, Valensi P, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilheto J, Schwarz PE, Roden M. A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes. Horm Metab Res 2010; 42 (Suppl. 01) S3-S36
- 6 Martin S, Martin E, Klug C, Weinauer F, Landgraf R, Rapp S. Diabetes study in Bavaria: known risk factors correlate with an increased level of HbA1c. Dtsch Med Wochenschr 2007; 132: 1315-1320
- 7 Lindstroem J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725-731
- 8 Saaristo T, Peltonen M, Keinänen-Kiukaanniemi S, Vanhala M, Saltevo J, Niskanen L, Oksa H, Korpi-Hyövälti E, Tuomilehto J. FIN-D2D Study Group. Int J Circumpolar Health 2007; 66: 101-112
- 9 Bergmann A, Li J, Wang L, Schulze J, Bornstein SR, Schwarz PE. A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res 2007; 39: 677-682
- 10 Charuruks N, Milintagas A, Watanaboonyoungcharoen P, Ariyaboonsiri C. Determination of reference intervals of HbA1c (DCCT/NGSP) and HbA1c (IFCC) in adults. J Med Assoc Thai 2005; 88: 810-816
- 11 Peter A, Fritsche A, Stefan N, Heni M, Häring HU, Schleicher E. Diagnostic Value of Hemoglobin A1c for Type 2 Diabetes Mellitus in a Population at Risk. Exp Clin Endocrinol Diabetes 2011; 119: 234-237
- 12 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 01) 62-69
- 13 Kerner W, Brückel J. Definition, Klassifikation und Diagnostik des Diabetes. mellitusDiabetol Stoffwechs 2008; 3 (Suppl. 02) 131-133
- 14 Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R, Giani G. High prevalence of undiagnosed diabetes in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46: 182-189
- 15 Meisinger C, Strassburger K, Heier M, Thorand B, Baumeister SE, Giani G, Rathmann W. Prevalence of undiagnosed diabetes and impaired glucose regulation in 35–59-year-old individuals in Southern Germany: the KORA F4 Study. Diabet Med 2010; 27: 360-362
- 16 Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819
- 17 Köstner I, Huppertz E, Hauner H, Schubert I. Direct Costs of Diabetes mellitus in Germany-CoDiM 2000–2007. Exp Clin Endocrinol Diabetes 2011; 119: 377-385
- 18 Li J, Bergmann A, Reimann M, Bornstein SR, Schwarz PEH. A More Simplified Finnish Diabetes Risk Score for Opportunistic Screening of Undiagnosed Type 2 Diabetes in a German Population with a Family History of the Metabolic Syndrome. Horm Metab Res 2009; 41: 98-103
- 19 Schwarz PEH, Li J, Lindstrom J, Tuomilehto J. Tools for Predicting the Risk of Type 2 Diabetes in Daily Practice. Horm Metab Res 2009; 41: 86-97
- 20 Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 2004; 47: 1566-1573
- 21 Herman WH, Engelgau MM, Zhang Y, Brown MB. Use of GHb (HbA(1c)) to screen for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23: 1207-1208
- 22 Papoz L, Favier F, Clabé A, Sanchez A, Le Moullec N. GHb (HbA(1c)) is more sensitive than fasting blood glucose as a screening test for diabetes. Diabetes Care 2000; 23: 1206-1207
- 23 International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334
- 24 Abdul-Ghani MA, Abdul-Ghani T, Müller G, Bergmann A, Fischer S, Bornstein S, DeFronzo RA, Schwarz P. Role of Glycated Hemoglobin in the Prediction of Future Risk of T2DM. J Clin Endocrin Metab 2011; 96: 2596-2600
- 25 Bennett CM, Guo M, Dharmage SC. HbA (1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 2007; 24: 333-343
- 26 Müller M, Ruf E, Weinauer F, Martin S, Becker C, Illig T, Döring A, Wichmann HE, Rapp S. The BSD Health Study: a pilot study to examine the comparability of Bavarian blood donors with the Bavarian general population by a comparison with KORA S4. Das Gesundheitswesen 2009; 71: 481-488
- 27 Lindström J, Neumann A, Sheppard KE, Gili-Januszewska A, Greaves CJ, Handke U, Pajunen P, Puhl S, Pölönen A, Rissanen A, Roden M, Stemper T, Tell-Hjellset V, Tuomilheto J, Velickiene D, Schwarz PE. on behalf of the IMAGE study group. Take action to prevent diabetes – the IMAGE toolkit for prevention of type 2 diabetes in Europe. Horm Metab Res 2010; 42 (Suppl. 01) S37-S55